Chitosan-Coated Oleuropein Nanoliposomes Enable Dose-Sparing Suppression of Serum Inflammatory Markers in a TNF-α-Induced Vascular Inflammation Model
CS-Ole-Lip is supported as a stable oral nanocarrier with enhanced anti-inflammatory pharmacodynamic activity and the mechanistic basis for the dose-sparing effect requires direct pharmacokinetic and molecular validation.